UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

International immunopharmacology, 2021-01, Vol.90, p.107226-107226, Article 107226

2021

Volltextzugriff (PDF)

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Gene therapy, 2017-02, Vol.24 (2), p.92-103

2017

Volltextzugriff (PDF)

Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro

Experimental and clinical endocrinology & diabetes, 2010-04, Vol.118 (4), p.237

2010

Volltextzugriff (PDF)

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Cancer gene therapy, 2014-03, Vol.21 (3), p.95-102

2014

Volltextzugriff (PDF)

Kick-starting the cancer-immunity cycle by targeting CD40

Oncoimmunology, 2015-01, Vol.4 (7), p.e1011484-e1011484

2015

Volltextzugriff (PDF)

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

Journal of immunotherapy, 2010-04, Vol.33 (3), p.225-235

2010

Volltextzugriff (PDF)

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Nature communications, 2021-07, Vol.12 (1), p.4127-4127, Article 4127

2021

Volltextzugriff (PDF)

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Cancers, 2021-06, Vol.13 (13), p.3116

2021

Volltextzugriff (PDF)

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

PloS one, 2021-09, Vol.16 (9), p.e0258041-e0258041

2021

Volltextzugriff (PDF)

An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Advanced therapeutics, 2022-07, Vol.5 (7), p.n/a

2022

Volltextzugriff (PDF)

Tumor-Specific Bacteriophages Induce Tumor Destruction through Activation of Tumor-Associated Macrophages

The Journal of immunology (1950), 2009-03, Vol.182 (5), p.3105-3111

2009

Volltextzugriff (PDF)

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity

Journal of immunotherapy (1997), 2008-01, Vol.31 (1), p.34

2008

Volltextzugriff (PDF)

Development and characterization of a novel autochthonous semi-spontaneous bladder cancer model by pathological evaluation, single cell sequencing and proteomic profiling

Urologic oncology, 2020-12, Vol.38 (12), p.896-896

2020

Volltextzugriff (PDF)

CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4 super(+) T-cell Immunity

Journal of immunotherapy, 2008-01, Vol.31 (1), p.34-42

2008

Volltextzugriff (PDF)

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

Frontiers in immunology, 2021-07, Vol.12, p.682492-682492

2021

Volltextzugriff (PDF)

Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?

Expert opinion on biological therapy, 2023-02, Vol.23 (2), p.115-117

Mangsbo, Sara M

2023

Volltextzugriff (PDF)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Journal of translational medicine, 2022-09, Vol.20 (1), p.1-419, Article 419

2022

Volltextzugriff (PDF)

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

BMC cancer, 2023-06, Vol.23 (1), p.605-605, Article 605

2023

Volltextzugriff (PDF)

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

PloS one, 2021-07, Vol.16 (7), p.e0253178

2021

Volltextzugriff (PDF)

Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer

European journal of immunology, 2017-02, Vol.47 (2), p.385-393

2017

Volltextzugriff (PDF)

Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

PloS one, 2024-05, Vol.19 (5), p.e0304890

2024

Volltextzugriff (PDF)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e004345

2022

Volltextzugriff (PDF)

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Oncoimmunology, 2020-01, Vol.9 (1), p.1730538-1730538

2020

Volltextzugriff (PDF)

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers

Nature communications, 2023, Vol.14 (1), p.1577-1577, Article 1577

2023

Volltextzugriff (PDF)

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection

The Lancet infectious diseases, 2022-07, Vol.22 (7), p.943-945

2022

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(73)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Kick-starting the cancer-immunity cycle by targeting CD40

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Tumor-Specific Bacteriophages Induce Tumor Destruction through Activation of Tumor-Associated Macrophages

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity

Development and characterization of a novel autochthonous semi-spontaneous bladder cancer model by pathological evaluation, single cell sequencing and proteomic profiling

CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4 super(+) T-cell Immunity

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer

Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection

Suchergebnisse filtern